无创通气治疗期间评估新型沟通装置的随机对照试验
该单中心随机对照试验纳入36例接受CPAP治疗的OSA门诊患者,评估口鼻面罩对沟通可懂度的影响及PAP沟通装置(SPEAX)的改善作用。与正常对话相比,CPAP下词语和语句可懂度分别相对下降52%(87% vs 41%)和57%(94% vs 40%)。与对照(sham装置)相比,干预组词语和语句可懂度分别相对提高75%(35% vs 61%,P < .001)和126%(33% vs 76%,P < .001),患者和伴侣感知的PAP舒适度也显著改善(P = .042和P = .0074)。
要点
- 在CPAP 10 cm H2O下,与正常对话相比,词语可懂度相对下降52%(87% vs 41%),语句可懂度相对下降57%(94% vs 40%)。
- 与sham装置对照相比,使用SPEAX沟通装置使词语可懂度相对提高75%(35% vs 61%,P < .001)。
- 与sham装置对照相比,使用SPEAX沟通装置使语句可懂度相对提高126%(33% vs 76%,P < .001)。
- 使用该装置使患者感知的PAP舒适度相对改善233%(15% vs 50%,P = .042),伴侣感知舒适度相对改善245%(20% vs 69%,P = .0074)。
- 该研究为单中心RCT,纳入36例OSA门诊患者,评估CPAP 10 cm H2O下的沟通可懂度。
适用人群与场景
- 36例门诊OSA患者,正在接受CPAP治疗,每个患者与一名伴侣配对参与评估。
- 研究场景为CPAP 10 cm H2O治疗期间,非急诊或ICU急性呼吸衰竭患者。
- 原文未明确列出排除标准。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 第一步:患者在CPAP 10 cm H2O下佩戴口鼻面罩进行对话,评估沟通可懂度。
- 第二步:随机分配至使用功能型PAP沟通装置(SPEAX,Ataia Medical)或sham装置,在CPAP下佩戴装置进行对话。
- 第三步:每阶段结束后,患者和伴侣分别完成Likert问卷调查,评估感知可懂度和舒适度。
- 原文未提及药物剂量或装置具体操作参数。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心随机对照试验,样本量36例门诊OSA患者,每个患者与伴侣配对。
- 干预与对照:功能型PAP沟通装置(SPEAX)vs sham装置,均在CPAP 10 cm H2O下使用。
- 主要终点:与正常对话相比,CPAP下词语可懂度相对下降52%(87% vs 41%),语句可懂度相对下降57%(94% vs 40%)。
- 与sham装置对照相比,干预组词语可懂度相对提高75%(35% vs 61%,P < .001),语句可懂度相对提高126%(33% vs 76%,P < .001)。
- 次要终点:患者感知PAP舒适度相对改善233%(15% vs 50%,P = .042),伴侣感知舒适度相对改善245%(20% vs 69%,P = .0074)。
证据类型、等级与局限
- 证据类型:单中心随机对照试验。
- 原文未述局限性。
对床旁实践的改变
- 该研究提示,在CPAP 10 cm H2O治疗期间使用SPEAX沟通装置可改善OSA门诊患者的词语和语句可懂度,并提高患者及伴侣感知的舒适度。
- 原文未评估该装置在急诊或ICU急性呼吸衰竭患者中的效果,适用人群限于接受CPAP治疗的OSA门诊患者。
- 原文未提及该装置对插管率、治疗依从性等临床结局的影响。
指南或共识出处
- Randomized Controlled Trial of a Novel Communication Device Assessed During Noninvasive Ventilation Therapy. Chest. ClinicalTrials.gov No.: NCT03795753.
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Noninvasive ventilation (NIV), a form of positive airway pressure (PAP) therapy, is the standard of care for various forms of acute respiratory failure (ARF). Communication impairment is a side effect of NIV, impedes patient care, contributes to distress and intolerance, and potentially increases intubation rates. This study aimed to evaluate communication impairment during CPAP therapy and demonstrate communication device improvement with a standardized protocol.
RESEARCH QUESTION: How does an oronasal mask affect communication intelligibility? How does use of an NIV communication device change this communication intelligibility?
STUDY DESIGN AND METHODS: A single-center randomized controlled trial (36 outpatients with OSA on CPAP therapy) assessed exposure to CPAP 10 cm H2O and PAP communication devices (SPEAX, Ataia Medical). Communication impairment was evaluated by reading selected words and sentences for partners to record and were tabulated as %words correct. Each outpatient-partner pair performed three assessments: (1) baseline (conversing normally), (2) mask baseline (conversing with PAP), and (3) randomized to functioning device (conversing with PAP and device) or sham device. After each stage, both outpatients and partners completed Likert surveys regarding perceived intelligibility and comfort.
RESULTS: While conversing with PAP, word and sentence intelligibility decreased relatively by 52% (87% vs 41%) and relatively by 57% (94% vs 40%), respectively, compared with normal conversation. Word and sentence intelligibility in the intervention arm increased relatively by 75% (35% vs 61%; P < .001) and by 126% (33% vs 76%; P < .001) higher than the control arm, respectively. The device improved outpatient-perceived PAP comfort relatively by 233% (15% vs 50%, P = .042) and partner-perceived comfort by relatively 245% (20% vs 69%, P = .0074).
INTERPRETATION: Use of this PAP communication device significantly improves both intelligibility and comfort. This is one of the first studies quantifying communication impairment during PAP delivery.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03795753; URL: www.clinicaltrials.gov.
参考来源
- Wong AI, Cheung PC, Zhang J, et al. Randomized Controlled Trial of a Novel Communication Device Assessed During Noninvasive Ventilation Therapy. Chest. 2020. PMID: 33011202. doi:10.1016/j.chest.2020.09.250
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。